-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 5-year average survival rate of non-small cell lung cancer ( NSCLC ) patients is about 15%, and more than 70% of NSCLC patients are diagnosed at an advanced stage that is not suitable for conventional chemoradiotherapy
.
In recent years, a series of breakthroughs have been made in tumor immunotherapy .
The 5-year average survival rate of non-small cell lung cancer ( NSCLC ) patients is about 15%, and more than 70% of NSCLC patients are diagnosed at an advanced stage that is not suitable for conventional chemoradiotherapy
At present, a number of PD-1/PD-L1 monoclonal antibodies have been approved worldwide, including Nivolumab, Atezolizumab, Avelumab and duvalumab Durvalumab has shown promising efficacy
TIGIT (T cell immunoreceptor with Ig and ITIM domains), the full name of T cell immunoglobulin and ITIM domain protein, is a novel immune checkpoint inhibitory receptor that exists in activated T cells in various cancers including NSCLC.
Tiragolumab is a monoclonal antibody and the world's first TIGIT antibody to be promoted to Phase III clinical trials
Tecentriq (Atezolizumab) is a monoclonal antibody and the first PD-L1 inhibitor approved by the FDA for clinical treatment of tumors
Dual immune checkpoint inhibitor combination therapy concept
The previous Phase 1 and Phase 2 clinical studies have achieved satisfactory results
.
Phase 2 study CITYSCAPE 01 is a prospective, randomized, double-blind, placebo-controlled Phase II trial evaluating tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) in first-line treatment of advanced stage Efficacy and safety in patients with NSCLC
The previous Phase 1 and Phase 2 clinical studies have achieved satisfactory results
A phase 3 clinical trial was carried out for this purpose
Regrettably, on March 30 this year, this clinical trial failed to meet the co-primary endpoint of progression-free survival (PFS) , nor did it meet the co-primary endpoint of overall survival(OS) in the interim analysis , and at the end of the program Statistical significance is unlikely to be reached in the analysis
.
.
statistics
About TIGIT
About TIGITAbout TIGITTIGIT stands for T cell immunoglobulin and ITIM domain protein (T cell immunoreceptor with Ig and ITIM domains), which is also an inhibitory receptor expressed on the surface of various types of T cells and NK cells
.
Tiragolumab is a fully human IgG1/kappa anti-TIGIT monoclonal antibody with an intact Fc region that blocks the binding of TIGIT to its ligand PVR and co-activating receptor CD226, theoretically restoring anti-tumor responses and enhancing anti-PD -L1 antibody efficacy
Tiragolumab is one of Roche's next-generation immune checkpoint inhibitors, and SKYSCRAPER-02 is one of five Phase III trials Roche has conducted for tiragolumab
.
At the same time, SCLC is a type of lung cancer with a high degree of malignancy, and many drugs with different mechanisms have also been broken into sand
Data from the SKYSCRAPER-02 study will be presented at a later medical meeting, but in general, the TIGIT target has not played a role in "sweeping the ground
.
" After PD-1/L1 immunotherapy, we need to solve how to expand the benefit population of immunotherapy, especially the new therapy in PD-1/L1 treatment non-responder or intolerant population.
It seems that TIGIT and LAG3 do not currently show Such potential
.
After PD-1/L1 immunotherapy, the industry has been exploring new immunotherapies, and TIGIT is one of the most popular targets, attracting international giants such as Roche, Gilead, Merck, Novartis, etc.
Development of specific dual-antibody therapy based on TIGIT
.
